EXACT SCIENCES CORP

EXAS
Country: United StatesPrice: $104.91Market Cap: $20.0B

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

3 / 11

NEUTRAL / FAIL

Median fair value

$50.50

-51.9% vs price

Models with upside

0 / 17

Positive margin of safety

Strongest signal

8 of 12 pass — Graham, Buffett, Lynch +1 more object

Key risk

All 13 investors flag EXAS's valuation

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2042 (Top 65.9%)NEUTRALFAILFAILFAILFAILFAILPASSFAILPASSNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/A-208.1%N/AN/AN/A-56.7%N/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-04-10

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-04-10

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-04-10

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-04-10

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-04-10

Latest source filing: 2026-02-13

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage67% pass✓ 11✗ 4▾

    8 of 12 pass — Graham, Buffett, Lynch +1 more object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.00, IC: -6.3x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities2.43
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=-6.3x, D/EBITDA=0.4x
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0027; #437/4210 (top 10.4%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✗ 28▾

    All 13 investors flag EXAS's valuation

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio8.3x
    ✗Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-1.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-1.1%, ROC=-30.9%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)40.7x
    ✗Dreman< 8x
    Price / Book Value per Share8.3x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=-0.6%
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=1.8%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=8.3x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share56.1x
    ✗Ackman<= 25
    Price vs. Trailing Low
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-1.04%; #3411/6340 (top 53.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+0.1199; #4635/6449 (top 71.9%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change-10.3%
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.1621; #3974/5247 (top 75.7%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+1.78%; #2290/4519 (top 50.7%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date
    ✗OshaughnessyTop 10% of eligible cross-section
  • Valuation models0% pass✗ 2▾

    EXAS overvalued: all 2 models price fair value below $104.91 (median $50.50)

    Munger fair value$34.05
    ✗Munger-208.1% margin vs $104.91
    Ackman fair value$66.96
    ✗Ackman-56.7% margin vs $104.91
  • Profitability6% pass✓ 7✗ 28▾

    15 of 16 flag EXAS's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)0/27 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)0/27 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-19.2%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-6.4% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-121.0M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-8.7%
    ✗Lynch> 15%
    EBIT / Enterprise Value-1.1%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-1.1%, ROC=-30.9%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-3.55%
    ✗PiotroskiROA > 0
    ROA Change YoY-17.36% -> -3.55% (delta: +13.81%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=8.39%, ROA=-3.55%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY69.5% -> 69.7%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue-6.3%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-8.7%
    ✗Dreman> 12%
    Margin of SafetyP/B=8.3x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity-19.3% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency0/17 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-6.4%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-8.7%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-8.6% (2023) -> -6.4% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 70.5% -> 69.7%, operating margin -8.6% -> -6.4%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-1.04%; #3411/6340 (top 53.8%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+38.61%; #1007/3702 (top 27.2%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity-8.66%; #3356/5226 (top 64.2%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.0518; #2625/5884 (top 44.6%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years0/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts14% pass✓ 2✗ 12▾

    Split decision: 11 FAIL · 3 NEUTRAL · 2 PASS

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (3/7)✗GreenblattRank #2042•PiotroskiNEUTRAL (F-Score 7)✗DremanFAIL (3/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)✓AckmanPASS (5/9)✗TempletonFAIL (3/8)✓SleepPASS (3/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (2/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
  • Growth25% pass✓ 5✗ 8▾

    6 of 8 flag EXAS's growth — Graham, Lynch, Dreman +3 more

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 2.4% vs Rev: 17.7%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction$-0.28 (2009) -> $-1.10 (2025)
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency0/17 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth17.7%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency3/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 70.5% -> 69.7%, operating margin -8.6% -> -6.4%
    ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR16.8%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Cash Flow30% pass✓ 4✗ 8▾

    7 of 10 flag EXAS's cash flow — Buffett, Dreman, Pabrai +4 more

    Free Cash Flow Proxy$-121.0M
    ✗BuffettPositive and growing
    FCF Positive and Growing$356.8M
    ✓LynchPositive and growing
    Operating Cash Flow$491.4M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=8.39%, ROA=-3.55%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)40.7x
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=1.8%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive4/17 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap1.8%
    ✗Ackman>= 4%
    Price / FCF per Share56.1x
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency4/17 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$356.8M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+1.78%; #2290/4519 (top 50.7%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Efficiency38% pass✓ 4✗ 7▾

    5 of 8 flag EXAS's efficiency — Buffett, Greenblatt, Munger +2 more

    Current Ratio2.43
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-19.3%
    ✗Buffett> 10%
    ROIC - WACC-29.3%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-30.9%
    ✗Greenblatt> 25%
    Current Ratio Change YoY2.15 -> 2.43
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.47x -> 0.55x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities2.43
    ✓Dreman> 1.5
    Return on Invested Capital-6.8%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-5.3%; FY2024: ROIC=-31.1%; FY2025: ROIC=-6.8%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest -6.8%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Healthcare
SIC Sector: Health Services
Size: Large Cap($20.0B)
Revenue: $3.2B+17.7% YoY
Net Income: $207.9M+79.8% YoY

Financial Snapshot

Operating Margin-6.4%
Return on Equity-8.7%
Debt / Equity0.00
Current Ratio2.43
EPS (Diluted)$-1.10
Shares Retired−2.8% / −5.2% 2y

Similar Companies

HCAHCA Healthcare, Inc.
$104.2B
THCTENET HEALTHCARE CORP
$22.8B
GHGuardant Health, Inc.
$20.5B
FMSFresenius Medical Care AG
$11.4B

Shareholder Return

Fiscal 2025

Issued 2.8% of shares last year, 5.2% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2025-12-31

2025-01-01 – 2025-12-31

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense.

Q4 FY 2025

2025-10-01 – 2025-12-31

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, capex.

Q3 FY 2025

2025-07-01 – 2025-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q2 FY 2025

2025-04-01 – 2025-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q1 FY 2025

2025-01-01 – 2025-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-13
FY 2024
Sources
  • 10-K · 2025-02-19
FY 2023
Sources
  • 10-K · 2024-02-21
FY 2022
Sources
  • 10-K · 2023-02-21
FY 2021
Sources
  • 10-K · 2022-02-22
Market Cap$20.0Bcurrent--------$19.5Best.$10.4Best.$11.9Best.$12.0Best.$13.3Best.
Revenue$3.2B↑18%$878.4M↑23%$850.7M↑20%$811.1M↑16%$706.8M↑11%$3.2B↑18%$2.8B↑10%$2.5B↑20%$2.1B↑18%$1.8B
Operating Income-$206.3M↑80%-$82.6M↑91%-$25.5M↑35%-$2.1M↑92%-$96.0M↑10%-$206.3M↑80%-$1.0B↓388%-$215.0M↑64%-$593.5M↑31%-$855.7M
Net Income-$207.9M↑80%-$86.0M↑90%-$19.6M↑49%-$1.2M↑93%-$101.2M↑8%-$207.9M↑80%-$1.0B↓404%-$204.1M↑67%-$623.5M↓5%-$595.6M
EPS (Diluted)----$-0.10↑52%$-0.01↑89%$-0.54$-1.10↑80%$-5.59↓395%$-1.13↑68%$-3.54↓2%$-3.48
Gross Margin69.7%70.1%↑2%68.6%69.3%70.8%69.7%69.5%↓1%70.5%↑3%68.3%↓8%74.0%
Operating Margin-6.4%↑83%-9.4%↑92%-3.0%↑46%-0.3%↑93%-13.6%↑19%-6.4%↑83%-38.0%↓342%-8.6%↑70%-28.5%↑41%-48.4%
ROE-8.7%↑80%————-8.7%↑80%-42.8%↓560%-6.5%↑68%-20.5%↓17%-17.6%
Total Debt$6.4M↓98%$6.4M↓98%$7.8M↓97%$9.3M↓96%$11.0M↓96%$6.4M↓98%$262.4M↑425%$50.0M↑576%$7.4M↓41%$12.5M
Shareholders' Equity$2.4B$2.4B$2.5B↓22%$2.5B↓23%$2.4B↓23%$2.4B$2.4B↓24%$3.1B↑3%$3.0B↓10%$3.4B
Current Ratio2.43↑13%2.43↑13%2.72↑29%2.89↑33%2.73↑67%2.43↑13%2.15↓8%2.32↓2%2.38↓14%2.76
Debt / Equity0.00↓98%0.00↓98%0.00↓96%0.00↓95%0.00↓95%0.00↓98%0.11↑587%0.02↑554%0.00↓34%0.00
Operating Cash Flow$491.4M↑133%$151.7M↑222%$219.9M↑59%$89.0M↓17%$30.8M↑137%$491.4M↑133%$210.5M↑35%$156.1M↑170%-$223.6M↓119%-$102.2M
Free Cash Flow$356.8M↑379%$120.4M↑1021%$190.0M↑69%$46.7M↓34%-$365.0K↑100%$356.8M↑379%$74.5M↑133%$31.9M↑107%-$438.0M↓84%-$238.0M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Healthcare

EXAS vs Peers — Financial Grading

Revenue$3.2BMedian
Net Income$207.9MBottom 25%
ROE-8.7%Bottom 25%
D/E0.00Median
Op. Margin-6.4%Bottom 25%
Curr. Ratio2.43Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
HCA Healthcare, Inc.HCA$104.2B$499.05$75.6B$6.8B-112.6%-7.7113.0%0.971/95/93/71/3F-Score 64/11
TENET HEALTHCARE CORPTHC$22.8B$286.03$21.3B$2.4B56.1%3.1216.5%1.761/94/93/73/3F-Score 65/11
Guardant Health, Inc.GH$20.5B$151.70$982.0M$416.3M419.2%-15.14-44.5%4.842/91/91/70/3F-Score 52/11
Fresenius Medical Care AGFMS$11.4B$22.03$23.1B$1.1B7.4%0.819.3%1.265/92/91/70/3F-Score 85/11
UNIVERSAL HEALTH SERVICES INCUHS$11.2B$194.07$17.4B$1.5B20.5%0.6511.5%1.054/96/95/71/3F-Score 76/11
DAVITA INC.DVA$11.0B$174.56$13.6B$746.8M-114.7%-15.7815.0%1.291/94/92/71/3F-Score 73/11
CHEMED CORPCHE$7.1B$548.20$2.5B$265.2M27.1%—13.4%1.054/97/93/71/3F-Score 66/11
RadNet, Inc.RDNT$6.0B$76.42$2.0B$18.7M-1.7%1.003.0%1.761/91/91/70/3F-Score 31/11